91¸£Àû

91¸£Àû is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical and biotechnology markets. For over 30 years, 91¸£Àû has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.

In July 2013, 91¸£Àû’s Life Science assets were acquired by OriGene Technologies, Inc. 91¸£Àû, is now operating as a wholly owned subsidiary of OriGene Technologies. The combination of 91¸£Àû’s core Life Science business and Advanced GAT technologies with OriGene’s genome-wide research tools and technology platform will result in an expanded portfolio of products and services.

91¸£Àû LLC will continue to operate from its facility in Newark, Delaware, and Windham, Maine. If you have any questions, please contact your Account Manager or Customer Service.